Rare Cancer News & Clinical Trials » Trial

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

Posted: August 11th, 2022, 2:00pm GMT

Conditions: Hepatobiliary Cancer; Pancreatic Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Ampullary Cancer; Pancreatic Carcinoma
Intervention: Diagnostic Test: ctDNA Blood Collection
Sponsor: University of California, Irvine
Not yet recruiting

The PLATON Network

Posted: August 5th, 2022, 2:00pm GMT

Conditions: Hepatocellular Cancer; Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; Oesophageal Cancer; Stomach Cancer
Intervention:
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting

Permalink for 'Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)'

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Posted: July 11th, 2022, 2:00pm GMT

Conditions: Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma
Interventions: Biological: Durvalumab; Drug: Gemcitabine; Drug: Nab paclitaxel; Biological: Tremelimumab; Drug: Propranolol; Drug: Cisplatin
Sponsor: AHS Cancer Control Alberta
Not yet recruiting

Permalink for 'An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma'

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Posted: July 7th, 2022, 2:00pm GMT

Condition: Extrahepatic Cholangiocarcinoma
Intervention: Drug: Toripalimab, Gemcitabine,Oxaliplatin
Sponsor: Xuhua Duan
Recruiting

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Posted: June 24th, 2022, 2:00pm GMT

Condition: Perihilar Cholangiocarcinoma
Intervention: Drug: PD-1antibody plus GEMOX
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Posted: June 23rd, 2022, 2:00pm GMT

Condition: Biliary Tract Cancer
Interventions: Drug: SMT-NK inj.+Pembrolizumab; Drug: Pembrolizumab
Sponsor: SMT bio Co., Ltd.
Recruiting

Permalink for 'The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Nab-paclitaxel Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer'

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Nab-paclitaxel Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Posted: June 16th, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsor: Inova Health Care Services
Not yet recruiting

CH-EUS in Diagnosis of Inoperable Bile Duct Tumors

Posted: June 14th, 2022, 2:00pm GMT

Conditions: Inoperable Disease; Bile Duct Cancer
Intervention: Procedure: Endoscopic ultrasound with fine needle biopsy
Sponsor: Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Recruiting

Treatment of ARB202 Advanced Gastrointestinal Cancer Patients

Posted: June 9th, 2022, 2:00pm GMT

Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer
Intervention: Drug: ARB202
Sponsor: Arbele Pty Ltd
Recruiting

Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center

Posted: June 3rd, 2022, 2:00pm GMT

Conditions: Incidence of Cholangiocarcinoma on Choledochal Cysts; Postoperative Complications in Choledochal Cysts; Choledochal Cyst Monitoring
Intervention:
Sponsor: María Teresa Moreno Asencio
Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Posted: June 2nd, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Binkui Li
Recruiting

Permalink for 'Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)'

Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)

Posted: May 27th, 2022, 2:00pm GMT

Conditions: Common Bile Duct Stricture; Jaundice; Malignant
Intervention:
Sponsor: Azienda Unità Sanitaria Locale della Romagna
Recruiting

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Posted: April 27th, 2022, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: HAIC combined with donafenib and sintilimab
Sponsor: Zhongda Hospital
Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Posted: April 22nd, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Toripalimab; Drug: Lenvatinib mesylate capsules; Drug: Placebo IV; Drug: Oral placebo; Drug: Oxaliplatin for injection; Drug: Gemcitabine hydrochloride; Drug: Cisplatin
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting

Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma

Posted: April 14th, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention:
Sponsors: Qilu Hospital of Shandong University; Jinan Central Hospital; Shandong Provincial Hospital; Jinan Military General Hospital
Recruiting

Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment

Posted: April 14th, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsor: Thomas Jefferson University
Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Posted: April 13th, 2022, 2:00pm GMT

Condition: Solid Tumors
Intervention: Drug: Bemarituzumab
Sponsor: Amgen
Not yet recruiting

Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand

Posted: April 11th, 2022, 2:00pm GMT

Conditions: Cholangiocarcinoma; Liver Fluke-Related Cholangiocarcinoma; Opisthorchiasis
Intervention: Behavioral: eCHEC program
Sponsors: McMaster University; Khon Kaen University; Global Alliance for Chronic Diseases (GACD); Canadian Institutes of Health Research (CIHR)
Not yet recruiting

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Posted: April 6th, 2022, 2:00pm GMT

Conditions: CNS Cancer; Head and Neck Cancer; GI Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; Breast Cancer
Intervention: Radiation: Pencil Beam Scanning Proton Therapy
Sponsor: The New York Proton Center
Recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Posted: April 5th, 2022, 2:00pm GMT

Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non Small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM438; Drug: Pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Posted: March 23rd, 2022, 2:00pm GMT

Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Intervention: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Recruiting

Predictors of Severity of Postoperative Pancreatic Fistula After Pancreatoduodenectomy

Posted: March 23rd, 2022, 2:00pm GMT

Condition: Post Operative Pancreatic Fistula
Intervention: Other: no intervention
Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Posted: March 23rd, 2022, 2:00pm GMT

Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Intervention: Biological: Neoantigen specific TCR-T cell drug product
Sponsor: Alaunos Therapeutics
Not yet recruiting

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Posted: March 22nd, 2022, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Yunfei Yuan
Recruiting

Permalink for 'Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma'

Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Posted: March 18th, 2022, 2:00pm GMT

Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsor: National Cancer Institute (NCI)
Not yet recruiting

Permalink for 'Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases'

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Posted: March 17th, 2022, 2:00pm GMT

Conditions: Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Posted: March 14th, 2022, 2:00pm GMT

Conditions: Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer
Intervention: Drug: PIPAC with Nal-IRI
Sponsors: University Hospital, Ghent; Kom Op Tegen Kanker; University Ghent
Not yet recruiting

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Posted: March 11th, 2022, 3:00pm GMT

Condition: Locally Advanced Solid Tumor
Intervention: Drug: TNG908
Sponsor: Tango Therapeutics, Inc.
Recruiting

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

Posted: March 4th, 2022, 3:00pm GMT

Conditions: Adverse Drug Event; Colon Cancer; Breast Cancer; Pancreas Cancer; Rectal Cancer; Gastric Cancer; Oesophageal Cancer; Bile Duct Cancer
Intervention: Genetic: DPYD genotype
Sponsors: University of Southern Denmark; Odense University Hospital
Recruiting

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Posted: March 3rd, 2022, 3:00pm GMT

Condition: Resectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Capecitabine; Device: Selective Internal Radiotherapy (SIRT); Procedure: Surgery
Sponsor: Center Eugene Marquis
Recruiting

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Posted: February 14th, 2022, 3:00pm GMT

Conditions: Biliary Tract Cancer (CCA); Intrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Capecitabine
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting

VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Posted: February 4th, 2022, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Intervention: Drug: VG161
Sponsor: Virogin Biotech Canada Ltd
Not yet recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Posted: January 31st, 2022, 3:00pm GMT

Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Posted: January 18th, 2022, 3:00pm GMT

Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Endometrial Cancer; Ovarian Carcinoma; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Interventions: Biological: Neoantigen specific TCR-T cell drug product; Biological: Aldesleukin (IL-2)
Sponsor: Alaunos Therapeutics
Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Posted: January 18th, 2022, 3:00pm GMT

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting

Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors

Posted: January 6th, 2022, 3:00pm GMT

Conditions: Breast Cancer; Uterine Cancer; Ovarian Cancer; Non Small Cell Lung Cancer (NSCLC); Cervical Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC), Except for Nasopharyngeal Carcinoma; Urothelial Cancer; Cholangiocarcinoma (CCA)
Intervention: Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
Sponsor: Genmab
Recruiting

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Posted: January 4th, 2022, 3:00pm GMT

Conditions: Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor
Intervention: Drug: EMB-01
Sponsors: Shanghai EpimAb Biotherapeutics Co., Ltd.; Labcorp Drug Development, Inc.
Recruiting

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Posted: January 3rd, 2022, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Derazantinib
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting

Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

Posted: December 28th, 2021, 3:00pm GMT

Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Lenvatinib Pill,Paclitaxel
Sponsors: National Health Research Institutes, Taiwan; National Cheng-Kung University Hospital; National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Chang Gung Memorial Hospital; China Medical University, Taiwan
Recruiting

A Study of DB-1303 in Advanced/Metastatic Solid Tumors

Posted: December 9th, 2021, 3:00pm GMT

Condition: HER2-positive Advanced Solid Tumor
Intervention: Biological: DB-1303
Sponsor: DualityBio Inc.
Recruiting

Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours.

Posted: November 24th, 2021, 3:00pm GMT

Condition: Immune System
Intervention: Other: blood samples
Sponsors: Centre Georges Francois Leclerc; Institut de Recherches Internationales Servier
Recruiting

HLA Typing and Tumor Neoantigen Identification for a Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Posted: November 18th, 2021, 3:00pm GMT

Conditions: Ovarian Cancer; Endometrial Cancer; Colo-rectal Cancer; Cholangiocarcinoma; Non-small Cell Lung Cancer; Pancreas Cancer
Intervention:
Sponsors: Alaunos Therapeutics; M.D. Anderson Cancer Center
Recruiting

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Posted: September 22nd, 2021, 2:00pm GMT

Conditions: Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma
Intervention: Device: high dose rate brachytherapy
Sponsor: M.D. Anderson Cancer Center
Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Posted: August 11th, 2021, 2:00pm GMT

Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Recruiting

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)

Posted: August 4th, 2021, 2:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Drug: Novel combination of chemotherapy and immunotherapy
Sponsor: University of Alabama at Birmingham
Recruiting

Combination Immunotherapy in Rare Cancers Under InvesTigation

Posted: July 21st, 2021, 2:00pm GMT

Conditions: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting

Deep Liver Phenotyping and Immunology Study

Posted: July 1st, 2021, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma
Intervention:
Sponsor: University of Oxford
Recruiting

Permalink for 'The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction.'

The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction.

Posted: June 28th, 2021, 2:00pm GMT

Condition: Malignant Biliary Obstruction
Interventions: Procedure: Intraductal Radio-Frequency Ablation; Device: Biliary Stent Placement
Sponsors: University Hospitals Dorset NHS Foundation Trust; Aquilant Services; The Christie NHS Foundation Trust
Not yet recruiting

Permalink for 'Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels'

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Posted: June 18th, 2021, 2:00pm GMT

Conditions: Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer; GI Carcinoma; Lung Cancer
Interventions: Drug: Standard of Care Chemotherapy; Procedure: Video-Assisted Thoracic Surgery (VATS); Procedure: Lobectomy; Radiation: Consolidative Radiation; Radiation: Ablation Treatment; Procedure: Resection or Excision; Procedure: Peritonectomy; Other: Transarterial Radioembolization
Sponsor: University of Chicago
Not yet recruiting

Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma

Posted: June 9th, 2021, 2:00pm GMT

Conditions: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration
Intervention: Drug: TT-00420
Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Posted: June 4th, 2021, 2:00pm GMT

Conditions: Mesothelioma; Glioblastoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Breast Cancer; Ovarian Cancer; Cervical Cancer; Endocervical Cancer; Colorectal Cancer; Esophageal Cancer
Interventions: Drug: NGM707; Drug: NGM707 plus pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Posted: June 1st, 2021, 2:00pm GMT

Condition: Advanced Solid Tumours
Interventions: Drug: RXC004; Biological: Denosumab
Sponsor: Redx Pharma Plc
Recruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Posted: June 1st, 2021, 2:00pm GMT

Conditions: Cancer Pain; Visceral Pain; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Small Intestine Cancer; Pancreas Cancer; Liver Cancer; Colon Cancer; Biliary Tract Cancer; Stomach Cancer; Rectum Cancer; Peritoneal Cancer; Gastrointestinal Cancer Metastatic; Gastrointestinal Cancers - Anus; Gastrointestinal Cancers - Stomach; Gastrointestinal Cancers - Colorectal; Gastrointestinal Cancers - Small Intestine; Small Intestine Cancer Stage III; Small Intestine Cancer Stage IV; Small Intestine Cancer, Recurrent; Pancreas Cancer, Stage III; Pancreas Cancer, Stage IV; Pancreas Cancer, Metastatic; Pancreas Cancer, Recurrent; Liver Cancer Stage IIIa; Liver Cancer Stage IIIb; Liver Cancer Stage IIIc; Liver Cancer Stage IV; Colon Cancer Stage III; Colon Cancer Stage IV; Stomach Cancer Stage III; Stomach Cancer Stage IV; Stomach Cancer Recurrent; Rectum Cancer, Recurrent; Gastrointestinal Cancers - Liver; Anal Cancer; Anal Cancer Stage III; Anal Cancer Stage IV; Anal Cancer Recurrent; Anal Cancer Metastatic; Anal Cancer, Stage IIIA; Anal Cancer, Stage IIIB; Appendix Cancer; Ampullary Cancer; Bile Duct Cancer; Bile Duct Cancer Stage III; Bile Duct Cancer Stage IV; Bile Duct Cancer Stage IVA; Bile Duct Cancer Stage IVB; Bile Duct Cancer Recurrent; Carcinoid Tumor; Carcinoid Tumor of Pancreas; Carcinoid Tumor of Large Intestine; Carcinoid Tumor of GI System; Carcinoid Tumor of Colon; Carcinoid Tumor of Liver; Carcinoid Tumor of Cecum; Carcinoid Tumor of Ileum; Carcinoid Tumor of Rectum; Carcinoid Tumor of the Small Bowel; Carcinoid Tumor of the Stomach; Large Intestine Cancer; Esophagus Cancer; Esophagus Cancer, Stage III; Esophagus Cancer, Stage IV; Esophagus Cancer, Recurrent; Gallbladder Cancer; Gallbladder Cancer Stage III; Gallbladder Cancer Stage IV; Gastric (Stomach) Cancer; Neuroendocrine Tumor; Peritoneum Cancer; Rectal Cancer; Esophagus Cancer, Stage I; Esophagus Cancer, Stage II; Gallbladder Cancer Stage I; Gallbladder Cancer Stage II; Bile Duct Cancer Stage I; Bile Duct Cancer Stage II
Intervention: Device: PICO G2 4k
Sponsors: Cedars-Sinai Medical Center; National Cancer Institute (NCI)
Recruiting

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Posted: May 20th, 2021, 2:00pm GMT

Conditions: HRD; Cholangiocarcinoma; Metastatic Cancer
Interventions: Drug: Niraparib; Drug: Dostarlimab
Sponsors: Walid Shaib, MD; Emory University; GlaxoSmithKline
Recruiting

Permalink for 'Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery'

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Posted: May 18th, 2021, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Floxuridine (FUDR); Device: Implanted Medical Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting

Photodynamic Therapy for Cholangiocarcinoma

Posted: April 26th, 2021, 2:00pm GMT

Condition: Cholangiocarcinoma Non-resectable
Intervention: Drug: Hematoporphyrin
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting

Endoscopic Ultrasound-Guided Gastroenterostomy for Malignant Gastric Outlet Obstruction

Posted: March 23rd, 2021, 2:00pm GMT

Condition: Malignant Gastric Outlet Obstruction
Intervention: Procedure: EUS-guided gastroenterostomy
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Posted: March 12th, 2021, 3:00pm GMT

Condition: Solid Tumor
Interventions: Drug: IDE397; Drug: Docetaxel; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Pemetrexed
Sponsor: IDEAYA Biosciences
Recruiting

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Posted: March 11th, 2021, 3:00pm GMT

Conditions: Uveal Melanoma; Cutaneous Melanoma; BAP1 Gene Mutation; Renal Cell Carcinoma; Mesothelioma; Hepatocellular Carcinoma; Cholangiocarcinoma; Meningioma Atypical
Intervention:
Sponsor: Mohamed Abdel-Rahman
Recruiting

Clinical Validation of an Immunocytochemistry Method Using MARS1

Posted: February 18th, 2021, 3:00pm GMT

Condition: Bile Duct Obstruction, Extrahepatic
Intervention: Diagnostic Test: Cytology staining
Sponsor: Gangnam Severance Hospital
Recruiting

Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Posted: February 8th, 2021, 3:00pm GMT

Conditions: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Bladder Cancer; Small-cell Lung Cancer; Prostate Cancer; Thyroid Cancer; Sarcoma; Gastric Cancer; Gallbladder Cancer
Interventions: Drug: TT-00420; Combination Product: Nab-Paclitaxel
Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting

$Permalink for 'Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma'$

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Posted: January 13th, 2021, 3:00pm GMT

Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Bintrafusp Alfa; Procedure: Biopsy; Radiation: Hypofractionated Radiation Therapy
Sponsor: M.D. Anderson Cancer Center
Recruiting

Infusion System for Hepatic Cancer

Posted: December 28th, 2020, 3:00pm GMT

Conditions: Colorectal Cancer Metastatic to Liver; Intrahepatic Cholangiocarcinoma
Intervention: Device: Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
Sponsor: Ronald DeMatteo, M.D.
Recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141

Posted: December 24th, 2020, 3:00pm GMT

Conditions: Solid Tumor; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Pancreatic Cancer; Biliary Tract Cancer; Cholangiocarcinoma; Metastatic Cancer
Interventions: Biological: BNT141; Drug: Nab-paclitaxel; Drug: Gemcitabine
Sponsor: BioNTech SE
Recruiting

$Permalink for 'Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy'$

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Posted: December 21st, 2020, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Intervention: Drug: STP705
Sponsors: Sirnaomics; Translational Drug Development
Recruiting

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Posted: December 17th, 2020, 3:00pm GMT

Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym024
Sponsor: Symphogen A/S
Recruiting

Permalink for 'Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies'

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Posted: November 24th, 2020, 3:00pm GMT

Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym022; Drug: Sym023; Drug: Irinotecan Hydrochloride
Sponsor: Symphogen A/S
Recruiting

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Posted: September 28th, 2020, 2:00pm GMT

Conditions: Pancreatic Cancer; Small Bowel Cancer; Colorectal Cancer; Melanoma; Non Small Cell Lung Cancer; Thyroid Cancer; Bladder Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Cholangiocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Glioblastoma; MAPK Gene Mutation; KRAS Activating Mutation; BRAF Gene Mutation; NRAS Gene Mutation; HRAS Gene Mutation; MEK Mutation; ERK Mutation
Intervention: Drug: Ulixertinib (BVD-523)
Sponsors: xCures; Cancer Commons
Available

Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer

Posted: September 23rd, 2020, 2:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Intervention: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Recruiting

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

Posted: September 16th, 2020, 2:00pm GMT

Condition: Advanced Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab Injection [Keytruda]; Drug: Lenvatinib Mesylate
Sponsors: Shanghai Jiahui International Hospital; Shanghai Zhongshan Hospital
Recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Posted: August 20th, 2020, 2:00pm GMT

Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Any Solid Tumor
Interventions: Drug: LY3410738; Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc.
Recruiting

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Posted: August 11th, 2020, 2:00pm GMT

Condition: Advanced Cholangiocarcinoma
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Available

Permalink for 'Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer'

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Posted: July 30th, 2020, 2:00pm GMT

Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Posted: July 23rd, 2020, 2:00pm GMT

Conditions: Hepatocellular Cancer; Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; Oesophageal Cancer; Stomach Cancer
Intervention: Diagnostic Test: FoundationOne®CDx and FoundationOne®Liquid
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Roche Pharma AG
Recruiting

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Posted: July 10th, 2020, 2:00pm GMT

Condition: HER2-amplified Biliary Tract Cancers
Interventions: Drug: ZW25 (Zanidatamab); Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay; Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay
Sponsors: Zymeworks Inc.; BeiGene, Ltd.
Recruiting

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Posted: July 7th, 2020, 2:00pm GMT

Conditions: Bladder Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Hepatocellular Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Pleural Neoplasm; Malignant Skin Neoplasm; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Thymus Neoplasm; Neuroendocrine Neoplasm; Thyroid Gland Carcinoma; Urothelial Carcinoma
Interventions: Procedure: Computed Tomography; Drug: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography
Sponsor: Jonsson Comprehensive Cancer Center
Recruiting

Hepatobiliary Tumors Tissue Samples Acquisition

Posted: June 24th, 2020, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Liver Cancer; Precancerous Condition; Benign Hepatobiliary Disease; Healthy, no Evidence of Disease
Interventions: Other: Gene expression analysis; Other: Genomic analysis; Other: Protein expression analysis; Other: Proteomic profiling; Other: Polymerase chain reaction; Other: Mass spectrometry; Other: Immunohistochemistry; Other: Metabolomics profiling; Other: Methylation and epigenetic analysis; Other: Liquid biopsy analysis; Other: Laboratory biomarker analysis
Sponsors: Peking Union Medical College Hospital; OrigiMed; GeneCast Biotechnology Co., Ltd.; YuceBio Technology Co., Ltd.
Recruiting

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Posted: June 12th, 2020, 2:00pm GMT

Conditions: Astrocytoma; Brain Cancer; Brain Metastases; Bladder Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Pleural Mesothelioma; Prostate Cancer; Sarcoma; Tongue Cancer; Thymic Carcinoma; Urinary Tract Cancer
Intervention: Drug: QBS10072S
Sponsors: Quadriga Biosciences, Inc.; Novotech (Australia) Pty Limited
Recruiting

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Posted: June 9th, 2020, 2:00pm GMT

Conditions: Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma
Intervention: Drug: BOLD-100 in combination with FOLFOX Chemotherapy
Sponsor: Bold Therapeutics, Inc.
Recruiting

Afatinib in Advanced NRG1-Rearranged Malignancies

Posted: June 1st, 2020, 2:00pm GMT

Condition: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Intervention: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Recruiting

Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors

Posted: May 22nd, 2020, 2:00pm GMT

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cysts; Pancreatic Endocrine Tumors; Chronic Pancreatitis; Cholangiocarcinoma, Extrahepatic; Ampullary Adenocarcinoma; Duodenal Adenocarcinoma
Interventions: Procedure: Robotic pancreaticoduodenectomy; Procedure: Open pancreaticoduodenectomy
Sponsors: Ruijin Hospital; Intuitive Surgical
Recruiting

Permalink for 'Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.'

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Posted: May 7th, 2020, 2:00pm GMT

Condition: Unresectable Cholangiocarcinoma
Interventions: Drug: Neoadjuvant Chemo-radiotherapy; Procedure: Liver Transplantation
Sponsor: Hospital Vall d'Hebron
Recruiting

Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Posted: April 27th, 2020, 2:00pm GMT

Condition: Gallbladder Cancer
Interventions: Combination Product: Shortened hydration time and dispensary of Akynzeo; Combination Product: Standard of care
Sponsors: Imperial College Healthcare NHS Trust; Chugai Pharma UK Limited
Recruiting

Permalink for 'Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy'

Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy

Posted: March 16th, 2020, 2:00pm GMT

Conditions: Primary Sclerosing Cholangitis; Cholestasis
Interventions: Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Drug: Placebo of Bezafibrate in addition to standard UDCA therapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting

Permalink for 'mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma'

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Posted: February 5th, 2020, 3:00pm GMT

Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Dexamethasone; Drug: Floxuridine; Device: Implanted Medical Device; Drug: Irinotecan; Drug: Leucovorin; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Recruiting

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Posted: January 23rd, 2020, 3:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; AstraZeneca
Recruiting

Permalink for 'Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)'

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Posted: December 18th, 2019, 3:00pm GMT

Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Posted: December 6th, 2019, 3:00pm GMT

Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Recruiting

Permalink for 'Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab'

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Posted: November 15th, 2019, 3:00pm GMT

Conditions: Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma
Interventions: Biological: Bevacizumab; Drug: Dasatinib; Drug: Fluorouracil; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: Anne Noonan
Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Posted: November 8th, 2019, 3:00pm GMT

Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsor: Antoinette J Wozniak, MD
Recruiting

Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

Posted: October 21st, 2019, 2:00pm GMT

Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Simvastatin 40mg; Drug: Placebo oral tablet
Sponsor: Annika Bergquist
Recruiting

Permalink for 'Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements'

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Posted: September 18th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
Interventions: Drug: TAS-120; Drug: Cisplatin/Gemcitabine
Sponsor: Taiho Oncology, Inc.
Recruiting

Permalink for 'Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma'

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Posted: September 12th, 2019, 2:00pm GMT

Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Ivosidenib; Drug: Pemigatinib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Posted: September 12th, 2019, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Available

Efficacy of Fistulotomy for Biliary Cannulation

Posted: July 30th, 2019, 2:00pm GMT

Conditions: Cholangiocarcinoma; Choledocholithiasis; Cholangitis; Pancreatic Cancer; Pancreatitis
Interventions: Procedure: Fistulotomy - High experienced.; Procedure: Fistulotomy - Low experienced.; Procedure: Conventional (guidewire) cannulation- High experienced; Procedure: Conventional (guidewire) cannulation - Low experienced
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting

Permalink for 'Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer'

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Posted: May 8th, 2019, 2:00pm GMT

Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting

Permalink for 'A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer'

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Posted: April 29th, 2019, 2:00pm GMT

Condition: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: Drug: ZW25 (Zanidatamab); Drug: Capecitabine; Drug: Cisplatin; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Bevacizumab; Drug: Gemcitabine
Sponsor: Zymeworks Inc.
Recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Posted: April 9th, 2019, 2:00pm GMT

Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; High Grade Ovarian Serous Adenocarcinoma
Interventions: Biological: gavo-cel; Drug: fludarabine; Drug: cyclophosphamide; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: TCR2 Therapeutics; Bristol-Myers Squibb
Recruiting

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Posted: March 18th, 2019, 2:00pm GMT

Conditions: Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting

Clinical Trial of Autologous Tcm Immunotherapy in ICC

Posted: January 29th, 2019, 3:00pm GMT

Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (100 unread)

Posted: August 11th, 2022, 2:00pm GMT

Posted: August 5th, 2022, 2:00pm GMT

Posted: July 11th, 2022, 2:00pm GMT

Posted: July 7th, 2022, 2:00pm GMT

Posted: June 24th, 2022, 2:00pm GMT

Posted: June 23rd, 2022, 2:00pm GMT

Posted: June 16th, 2022, 2:00pm GMT

Posted: June 14th, 2022, 2:00pm GMT

Posted: June 9th, 2022, 2:00pm GMT

Posted: June 3rd, 2022, 2:00pm GMT

Posted: June 2nd, 2022, 2:00pm GMT

Posted: May 27th, 2022, 2:00pm GMT

Posted: April 27th, 2022, 2:00pm GMT

Posted: April 22nd, 2022, 2:00pm GMT

Posted: April 14th, 2022, 2:00pm GMT

Posted: April 14th, 2022, 2:00pm GMT

Posted: April 13th, 2022, 2:00pm GMT

Posted: April 11th, 2022, 2:00pm GMT

Posted: April 6th, 2022, 2:00pm GMT

Posted: April 5th, 2022, 2:00pm GMT

Posted: March 23rd, 2022, 2:00pm GMT

Posted: March 23rd, 2022, 2:00pm GMT

Posted: March 23rd, 2022, 2:00pm GMT

Posted: March 22nd, 2022, 2:00pm GMT

Posted: March 18th, 2022, 2:00pm GMT

Posted: March 17th, 2022, 2:00pm GMT

Posted: March 14th, 2022, 2:00pm GMT

Posted: March 11th, 2022, 3:00pm GMT

Posted: March 4th, 2022, 3:00pm GMT

Posted: March 3rd, 2022, 3:00pm GMT

Posted: February 14th, 2022, 3:00pm GMT

Posted: February 4th, 2022, 3:00pm GMT

Posted: January 31st, 2022, 3:00pm GMT

Posted: January 18th, 2022, 3:00pm GMT

Posted: January 18th, 2022, 3:00pm GMT

Posted: January 6th, 2022, 3:00pm GMT

Posted: January 4th, 2022, 3:00pm GMT

Posted: January 3rd, 2022, 3:00pm GMT

Posted: December 28th, 2021, 3:00pm GMT

Posted: December 9th, 2021, 3:00pm GMT

Posted: November 24th, 2021, 3:00pm GMT

Posted: November 18th, 2021, 3:00pm GMT

Posted: September 22nd, 2021, 2:00pm GMT

Posted: August 11th, 2021, 2:00pm GMT

Posted: August 4th, 2021, 2:00pm GMT

Posted: July 21st, 2021, 2:00pm GMT

Posted: July 1st, 2021, 2:00pm GMT

Posted: June 28th, 2021, 2:00pm GMT

Posted: June 18th, 2021, 2:00pm GMT

Posted: June 9th, 2021, 2:00pm GMT

Posted: June 4th, 2021, 2:00pm GMT

Posted: June 1st, 2021, 2:00pm GMT

Posted: June 1st, 2021, 2:00pm GMT

Posted: May 20th, 2021, 2:00pm GMT

Posted: May 18th, 2021, 2:00pm GMT

Posted: April 26th, 2021, 2:00pm GMT

Posted: March 23rd, 2021, 2:00pm GMT

Posted: March 12th, 2021, 3:00pm GMT

Posted: March 11th, 2021, 3:00pm GMT

Posted: February 18th, 2021, 3:00pm GMT

Posted: February 8th, 2021, 3:00pm GMT

Posted: January 13th, 2021, 3:00pm GMT

Posted: December 28th, 2020, 3:00pm GMT

Posted: December 24th, 2020, 3:00pm GMT

Posted: December 21st, 2020, 3:00pm GMT

Posted: December 17th, 2020, 3:00pm GMT

Posted: November 24th, 2020, 3:00pm GMT

Posted: September 28th, 2020, 2:00pm GMT

Posted: September 23rd, 2020, 2:00pm GMT

Posted: September 16th, 2020, 2:00pm GMT

Posted: August 20th, 2020, 2:00pm GMT

Posted: August 11th, 2020, 2:00pm GMT

Posted: July 30th, 2020, 2:00pm GMT